Low Seroconversion after One Dose of AS03-Adjuvanted H1N1 Pandemic Influenza Vaccine in Solid-Organ Transplant Recipients. Issue 1 (2013)

• Record Type: Journal Article
• Authors: Resende, Mariangela R; Husain, Shahid; Gubbay, Jonathan; Singer, Lianne; Cole, Edward; Renner, Eberhard L; Rotstein, Coleman
• Is Part Of: Canadian journal of infectious diseases & medical microbiology =. Volume 24:Issue 1(2013)
• Page Start: e7
• Page End: e10
• Publication Date: 2013
• Subjects: Communicable diseases -- Periodicals; Infection -- Periodicals; Communicable diseases; Infection; Communicable Diseases; Communicable Disease Control; Electronic journals; Periodicals; Fulltext; Internet Resources; Periodicals; 616.9
• DOI: 10.1155/2013/256756
• Languages: English
• ISSNs: 1712-9532

Abstract

Abstract : BACKGROUND: Immunocompromised individuals are more susceptible to complications produced by influenza infection. As a result, solid-organ transplant (SOT) recipients were targeted as a priority group to receive AS03-adjuvanted H1N1 influenza vaccine during 2009. OBJECTIVE: To evaluate seroconversion after one dose of adjuvanted pandemic influenza H1N1 (pH1N1) vaccine in SOT recipients. METHODS: Adult SOT recipients were enrolled to receive one 3.75 μg dose of adjuvanted pH1N1 vaccine. Serological status was tested using a hemagglutination inhibition assay before and two and four weeks postvaccination. RESULTS: The five SOT recipients (one liver, two kidney and two lung transplants) had a median age of 50 years (range 36 to 53 years), and three were male, who were a median time of three years (range two months to 15 years) post-transplant. All patients were on a double or triple immunosuppressive regimen. The prevaccination pH1N1 titre was 1:10 in four patients and 1:40 in one patient. Seroprotection was observed only in one patient, with a rise in titre from 1:40 at baseline to 1:320 at both two and four weeks after vaccination. This lung transplant recipient had documented previous infection with pH1N1. CONCLUSION: Results of the present small study call into question whether one dose of adjuvanted pH1N1 vaccine can provide seroprotection in SOT recipients.